window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-108383172-1'); Skip to content
Novigenix Logo Novigenix Logo
  • About us
    • Our Story
    • Team
    • Compliance
    • Commitment to ESG
  • LITOSeek™
    • LITOSeek Platform
    • Translational Medicine
  • News
  • Contact

Formulaire de commande Unilabs

By Margot Naëgelé|2018-07-20T09:30:43+02:0020 July 2018|

Share this content

FacebookXLinkedInEmail

About the Author: Margot Naëgelé

Recents posts

  • Novigenix AI to Present Clinical Data at AACR 2026 Linking Immuno-Pharmacodynamics to Radioligand Therapy Response 14 April 2026
  • Novigenix AI Spin-Out to Accelerate AI-Powered Immune Intelligence 6 March 2026
  • Novigenix AI awarded EUR 1.8M in the groundbreaking BRECISE IHI Consortium to industrialize AI-powered liquid biopsy for prediction of immunotherapy response 31 March 2025
  • New study reveals novel multi-omics approach with unprecedented treatment response prediction in metastatic urothelial cancer 11 March 2025
  • Breakthrough study reveals blood transcriptomic alternations for early detection of colorectal cancer 27 November 2024

Novigenix AI

Novigenix AI is a pioneering TechBio delivering liquid biopsy multi-omic solutions powered by the LITOSeek™ AI-RNA analytics platform to accelerate early cancer detection and development of effective therapies for better patient outcomes.

Contact us

  • Route de la Corniche 3
    Phenyl Building
    CH-1066 Epalinges
    Switzerland
  • partnerships@novigenix.com

Follow us on LinkedIn

Recent posts

  • Novigenix AI to Present Clinical Data at AACR 2026 Linking Immuno-Pharmacodynamics to Radioligand Therapy Response
  • Novigenix AI Spin-Out to Accelerate AI-Powered Immune Intelligence

Newsletter

COPYRIGHT 2026 NOVIGENIX AI | ALL RIGHTS RESERVED | PRIVACY POLICY | POWERED BY AGENCE-ACP |
Page load link
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Learn more Ok

Privacy Notice

Go to Top